Compare Annaly Capital Management, Inc. (NLY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Annaly Capital Management, Inc. trades at $22.83 (market cap $17.12B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Annaly Capital Management, Inc. is far larger — about 9.2× Recursion Pharmaceuticals Inc's market cap, and Annaly Capital Management, Inc. pays a 13.2% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NLY | RXRX | |
|---|---|---|
Market Cap | $17.12B | $1.86B |
Sector | Financials | Health |
52-Week High | $24.40 | $6.79 |
52-Week Low | $20.21 | $2.84 |
Dividend Yield | 13.2% | — |
Enterprise Value | — | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $22.72, down 0.39% today, with a technical bearish signal but strong fundamentals including a P/E of 5.49 and ROE of 20.66%. Recent earnings beats and a $0.75 dividend highlight operational strength, though cash flow volatility and high leverage pose risks.
Outlook remains positive with analyst consensus at Buy (57% of 28 analysts) and a $24.33 price target, offering ~7% upside. Key risks include interest rate sensitivity and debt levels, but diversified mortgage assets and consistent dividend coverage support income appeal.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
